Abrocitinib
Who holds supplier records for Abrocitinib? 4 organisations hold a current record for Abrocitinib: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (2), China (1) and Spain (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Abrocitinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/abrocitinib
Reading the evidence
- 4 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 3 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Abrocitinib expires 14 Jan 2036. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (4)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Abrocitinib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- CHANGZHOU PHARMACEUTICAL FACTORYChina Company GMP cert on recordActive DMF 39291 · latest filing Dec 2023
- MAITHRI DRUGS PRIVATE LTDIndia Company GMP cert on recordActive DMF 41402 · latest filing Feb 2025
- MICRO LABS LTDIndia Company GMP cert on recordActive DMF 41868 · latest filing Jun 2025
- MOEHS IBERICA SLSpainActive DMF 38879 · latest filing Sept 2023
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (3 listed products contain Abrocitinib). The latest listed patent expires 14 Jan 2036. The latest listed exclusivity runs to 14 Jan 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Abrocitinib is an oral selective inhibitor of Janus kinase 1 (JAK1), approved for the treatment of moderate-to-severe atopic dermatitis. It works by modulating the immune response involved in the pathogenesis of the disease.
Chemical identity
- IUPAC name
- N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
- Canonical SMILES
- CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3
- InChIKey
- IUEWXNHSKRWHDY-UHFFFAOYSA-N
- Synonyms
- Cibinqo API, cibinqo, pf-04965842
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Janus Kinase Inhibitor
- Mechanism of action
- Janus Kinase Inhibitors; P-Glycoprotein Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Abrocitinib?
4 organisations hold an active US FDA Type II Drug Master File or a CEP for Abrocitinib: CHANGZHOU PHARMACEUTICAL FACTORY (China), MAITHRI DRUGS PRIVATE LTD (India), MICRO LABS LTD (India) and MOEHS IBERICA SL (Spain). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Abrocitinib Drug Master Files are active?
CHANGZHOU PHARMACEUTICAL FACTORY (DMF 39291), MAITHRI DRUGS PRIVATE LTD (DMF 41402), MICRO LABS LTD (DMF 41868) and MOEHS IBERICA SL (DMF 38879). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Abrocitinib?
Yes. The latest patent listed for an approved US product containing Abrocitinib expires 14 Jan 2036, across 3 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Abrocitinib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Abrocitinib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.